{"entity":{"id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","aka":["LITESPARK-043"],"tldr":"A phase 3 trial of Belzutifan, Nivolumab, Lenvatinib and Cabozantinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) is a phase 3 interventional study registered as NCT07405164 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2026-03-23 and due to reach its primary completion in 2034-01-14. Interventions recorded: Belzutifan, Nivolumab, Lenvatinib and Cabozantinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07405164","url":"https://clinicaltrials.gov/study/NCT07405164"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["belzutifan","nivolumab","lenvatinib","cabozantinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07405164","phase":"3","setting":"A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT07405164","source":"https://clinicaltrials.gov/study/NCT07405164","fetchedAt":"2026-10-07T16:55:43.582Z","studySha256":"1e95eafaf65b93b965f76cf4a6817f4f2abc3d327938f9a26e4ee050b41f0bfb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":450,"enrolmentType":"ESTIMATED","siteCount":54,"recruitingSiteCount":47,"countries":["Australia","Belgium","Brazil","Canada","Chile","Czechia","Denmark","Finland","France","Hungary","Israel","Japan","Netherlands","New Zealand","Poland","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom","United States"]}],"started":"2026-03-23","startedType":"actual","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07405164/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}